$0.58
-0.04 (-6.53%)
Open$0.64
Previous Close$0.63
Day High$0.64
Day Low$0.58
52W High$14.71
52W Low$0.58
Volume—
Avg Volume295.7K
Market Cap5.37M
P/E Ratio—
EPS$-17.72
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3,516.9% upside
Current
$0.58
$0.58
Target
$21.13
$21.13
$13.63
$21.13 avg
$23.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.00M | 1.99M | 1.61M |
| Net Income | -74,230 | -69,635 | -62,110 |
| Profit Margin | -3.7% | -3.5% | -3.9% |
| EBITDA | -116,342 | -139,946 | -107,891 |
| Free Cash Flow | -67,743 | -57,560 | -72,298 |
| Rev Growth | +11.8% | +24.3% | -3.3% |
| Debt/Equity | 0.69 | 0.66 | 0.82 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |